Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

S Deshayes1, M Mahévas2, B Godeau2

  • 1Service de Médecine Interne, Normandie Université, UNICAEN, CHU de Caen Normandie, Caen, France; Service de Médecine Interne, Centre de Référence des Cytopénies Auto-Immunes de l'Adulte, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris, Université Paris Est Créteil, Créteil, France.

La Revue De Medecine Interne
|July 19, 2020
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Erratum to "Haematopoietic stem cell transplantation in the treatment of autoimmune diseases" [Rev. Med. Interne 29 (2008) 115-121]].

La Revue de medecine interne·2025
Same author

[French internal medicine is at a turning point in its history. Summary of the 2024 French Internal Medicine meeting].

La Revue de medecine interne·2024
Same author

Intravenous immunoglobulin as a rescue therapy for severe adult autoimmune hemolytic anemia: Results from a French multicenter observational study.

American journal of hematology·2024
Same author

Cutaneous manifestations of monogenic auto-inflammatory diseases: An international cohort study from the Juvenile Inflammatory Rheumatism cohort.

Journal of the American Academy of Dermatology·2022
Same author

Early infectious risk in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis according to remission-induction therapy.

Scandinavian journal of rheumatology·2022
Same author

A descriptive study of IgG4-related disease in children and young adults.

Autoimmunity reviews·2022
Same journal

[Abdominal pain, fever and arthralgia in a 49-year-old woman].

La Revue de medecine interne·2026
Same journal

[Cardiorespiratory functional disorders: A transnosologic approach].

La Revue de medecine interne·2026
Same journal

[Diagnostic evaluation for suspected polycythemia].

La Revue de medecine interne·2026
Same journal

Heart involvements in systemic sclerosis beyond pulmonary hypertension: From conduction, rhythm and function defects to coronary artery disease.

La Revue de medecine interne·2026
Same journal

[Acute intermittent porphyria: When diagnostic errance jeopardizes patient health].

La Revue de medecine interne·2026
Same journal

Autosomal dominant polycystic kidney disease: Current perspectives in 2026.

La Revue de medecine interne·2026
See all related articles

Rituximab offers a sustained response in 30% of immune thrombocytopenia (ITP) patients. Retreatment is effective and generally well-tolerated, though predictors for long-term success are needed.

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Rituximab is an established off-label second-line treatment for immune thrombocytopenia (ITP).
  • Initial response rates to rituximab in ITP range from 60% to 70%, with a high relapse rate in half of responders.
  • A sustained response at 5 years is observed in approximately 30% of patients with persistent or chronic ITP.

Purpose of the Study:

  • To evaluate the long-term efficacy and safety of rituximab in adult ITP.
  • To identify predictors of sustained response to rituximab therapy.
  • To discuss the role of retreatment and future research directions for rituximab in ITP.

Main Methods:

  • Review of existing literature on rituximab use in ITP.
  • Analysis of response rates, relapse patterns, and long-term outcomes.
Keywords:
Immune thrombocytopeniaPurpura thrombopénique immunologiqueRituximab

Related Experiment Videos

  • Assessment of safety data, including adverse events and infections.

    • Main Results:

    • One course of rituximab (375 mg/m²/week for 4 weeks or 2x1000 mg infusions) can lead to sustained responses in 30% of ITP patients at 5 years.
    • Retreatment with rituximab demonstrates similar or improved efficacy and duration of response.
    • Rituximab is generally well-tolerated, with mild infusion-related events being most common; severe infections are infrequent and often associated with other risk factors.

    Conclusions:

    • Rituximab is a valuable option for chronic ITP, particularly for patients achieving sustained responses.
    • Lack of robust predictors for long-term response necessitates individualized treatment decisions.
    • Further research, including head-to-head trials and studies on combination/maintenance therapy, is required to optimize rituximab's role in ITP management.